LONDON (Alliance News) - Clinigen Group PLC on Tuesday said its Idis Global Access (GA) division has signed an exclusive supply agreement with specialist healthcare company BTG PLC.
Under the deal, the Clinigen division will manage BTG's critical care portfolio across Europe and into some emerging markets in Asia. No financial details were given.
The agreement extends the four-year partnership Clinigen has with fellow London-listed BTG to provide early access programmes, focused on supplying selected countries in Europe using a Managed Access programme. The existing deal enables healthcare professionals to access BTG's antidote products for patients who have no other treatment options available to them.
The new agreement, however, increases the geographic scope of the partnership to include all of Europe as well as to supply the DigiFab product, an antidote for life-threatening digoxin toxicity, in the UK on a commercial basis. The partnership will also include some markets in Asia.
"This is a notable exclusive supply agreement for Idis GA. It not only expands our existing partnership with BTG but it is also the first agreement that capitalises on the complementary nature of our Managed Access and Global Access divisions," said Steve Glass, Clinigen's chief commercial officer for North America and Europe.
"It demonstrates the value of our unique, synergistic businesses which enables us to provide safe and ethical access to a medicine throughout its lifecycle - from development to approval, to launch and beyond," Glass added.
By Hannah Boland; hannahboland@alliancenews.com; @Hannaheboland
Copyright 2016 Alliance News Limited. All Rights Reserved.
